Is the purchase of Mavakatai (Maifantuo) self-pay or medical insurance reimbursement and cost calculation?

Mavacamten is a new oral small molecule drug for hypertrophic cardiomyopathy (HCM). It can reduce excessive cardiac contraction and improve cardiac function and exercise tolerance by regulating the activity of cardiac contractile proteins. With its domestic launch, Mavakatai Capsules have been included in my country's medical insurance system, which means that eligible patients can reduce the financial burden of treatment through medical insurance reimbursement. The specific reimbursement ratio and co-pay amount will vary depending on regional policies. Patients can consult local hospitals or pharmacies for detailed information.

In terms of price, the market price of the European version of the original drug of Mavakaita Capsules is between RMB 20,000 and more than 50,000 yuan, while the price of the American version of the original drug is even higher, about RMB 60,000. Due to the high price, out-of-pocket purchase may cause greater financial pressure on some patients. Therefore, medical insurance reimbursement is of great significance in improving drug accessibility and reducing patients' financial burden. Before using it, patients should reasonably calculate the out-of-pocket amount based on their personal medical insurance policy and treatment plan to facilitate budget arrangements.

In overseas markets, there are also generic versions of Mavakaita capsules on the market. For example, the price of a box of the Laos Lucius version of Mavakatai generic drug is about more than 1,000 yuan, which is much lower than the original drug. At the same time, the ingredients of the drug are basically the same as the original drug. This provides a feasible option for patients with limited financial conditions or those who purchase drugs overseas. However, before use, they need to ensure that the source of the drugs is regular and reliable, and follow the doctor's guidance to use the drugs rationally.

Taken together, Mavakatai already has medical insurance support in China, and patients can reduce their financial burden through medical insurance reimbursement, while overseas original drugs and generic drugs provide diversified choices for patients with different needs. During the specific purchase and medication process, a scientific and reasonable drug purchase and medication plan should be formulated based on medical insurance policies, drug prices and one's own economic situation to ensure the continuity, safety and maximum efficacy of treatment.

Reference link:https://www.drugs.com